TIL - NASDAQ
Instil Bio, Inc.
$8.10
-0.84%Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
At a Glance
Live SnapshotInstil Bio, Inc. Management Team
Mr. Bronson Crouch
Chairman & Chief Executive Officer
Compensation
$1,652,020
Dr. Sandeep Laumas M.D.
Chief Financial Officer & Chief Business Officer
Compensation
$1,018,399
Instil Bio, Inc. Insider Positioning
During the last 12 months, insiders have sold $298K worth of TIL shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
12.5K
297.57K
-298K
-$298K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Laumas Sandeep
Officer: Cfo And Cbo
$298K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $298K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
TIL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 14, 2025 | May 28, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 24, 2023 | June 14, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | March 30, 2022 | May 20, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.